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ABSTRACT: An integrated batch and continuous flow process has been developed for the gram-scale synthesis of goniothalamin.
The synthetic route hinges upon a telescoped continuous flow Grignard addition followed by an acylation reaction capable of
delivering a racemic goniothalamin precursor (16) (20.9 g prepared over 3 h), with a productivity of 7 g·h−1. An asymmetric Brown
allylation protocol was also evaluated under continuous flow conditions. This approach employing (−)-Ipc2B(allyl) provided an (S)-
goniothalamin intermediate in 98% yield and 91.5% enantiomeric excess (ee) with a productivity of 1.8 g·h−1. For the final step, a
ring-closing metathesis reaction was explored under several conditions in both batch and flow regimes. In a batch operation, the
Grubbs second-generation was shown to be effective and highly selective for the desired ring closure product over those arising from
other modes of reactivity, and the reaction was complete in 1.5 h. In a flow operation, reactivity and selectivity were attenuated
relative to the batch mode; however, after further optimization, the residence time could be reduced to 16 min with good selectivity
and good yield of the target product. A tube-in-tube reactor was investigated for in-situ ethylene removal to favor ring-closing over
cross-metathesis, in this context. These results provide further evidence of the utility of flow chemistry for organometallic processing
and reaction telescoping. Using the developed integrated batch and flow methods, a total of 7.75 g of goniothalamin (1) was
synthesized.
1. INTRODUCTION
Chemotherapy plays a pivotal role in cancer treatment,
improving the quality of life and increasing patient survival.
However, the drug resistance of antineoplastic drugs and their
high toxicity are some of the limitations of the current
chemotherapy treatments. Due to these reasons, drug
discovery programs have made efforts to deliver new
candidates with high selectivity and low off-target cytotoxicity
for cancer treatment. In most cases, such new candidates are
inspired by natural compounds due to their limitless chemical
diversity and a broad biological profile.1 To date, more than
50% of all approved small-molecule drugs have been
structurally inspired by isolated natural compounds.2 More-
over, ca. 80% of all antitumor agents used in the clinic are
derived from natural products.3
Accordingly, the natural product goniothalamin (1) has
been the object of study of various medicinal chemistry
programs for several years.4 Goniothalamin is a secondary
metabolite obtained from the species of the genus
Goniothalamus.5 This styryl lactone exhibits important
antiproliferative and cytotoxic effects on several tumor cell
types, such as lung, breast, kidney, prostate, liver, and
leukemia.6 Due to its wide biological profile, many medicinal
studies have explored goniothalamin as a chemical platform to
the design of new drug candidates and to understand their in
vitro mode of action (Scheme 1A).7
Using a solid tumor experimental model in vivo assay, our
group has demonstrated that both non-natural (R)-1 and
natural (S)-1, as well as its racemic-1 form, present
antiedematogenic and inhibitory activity against the prolifer-
ation of Ehrlich solid tumor cells.8 No evidence for toxic effects
was found, and similar activity profiles were observed for
racemic-1, (R)-1, and (S)-1 against NCI-ADR/RES, NCI-460,
786-0, and U251 cancer cells.8
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Concerning the synthesis of (±)-goniothalamin, we have
noted the lack of studies focusing on new strategies for the
gram-scale synthesis of 1. In many studies, 1 was used as a
starting material for the synthesis of goniothalamin derivatives,
or the same reaction sequence was employed for the
preparation of new analogues,6b,7 which shows the importance
of a robust and scalable method to accumulate 1. In addition,
gram quantities of 1 are required for more complete and in-
depth in vivo studies regarding the real potential of 1 as a drug
candidate for cancer treatment. Bearing this in mind,
continuous flow processing offers a great opportunity for the
scaling-up of the synthesis of goniothalamin (1).
Flow chemistry has emerged in both academia and industry
as a promising enabling technology for organic synthesis,
providing several advantages in comparison to traditional batch
processes for organic and inorganic synthesis.9 One of the
most attractive benefits in a continuous flow approach is the
opportunity to integrate several reaction steps (the so-called
telescoped synthesis) to rapidly generate focused libraries of
bioactive compounds as well as enough material for clinical
trials in medicinal chemistry programs.10 Recently, our group
has demonstrated the telescoped synthesis of highly sub-
stituted 3-thio-1,2,4-triazoles, including their gram-scale
preparation and application to the continuous flow synthesis
of an API.11 Integration of processing steps through telescoped
reactions allows for the expedient preparation of target
compounds since there is no need for intermediate isolation,
which also leads to reduced waste generation through the
reduction in solvent use.11 Indeed, the synthesis of many
natural products and biologically active compounds has been
the target of multistep flow chemical processes.12
In this context, we demonstrate herein an improved process
for the multigram synthesis of (±)-goniothalamin (1) in a
continuous flow regime (Scheme 1B). Since the racemic
mixture of 1 exhibited a similar in vivo antitumor profile
compared to both enantiomers and (S)-goniothalamin (S)-1
showed higher potency in vitro than (R)-1 against kidney
cancer cell proliferation (786-0) with IC50 = 4 nM,
6b both
racemic and asymmetric routes (for the S enantiomer) were
explored under continuous flow conditions.
Scheme 1. Goniothalamin and Derivatives (A); the Proposed Study (B)
Scheme 2. Previous Synthesis of Racemic Goniothalamin (1) in the Batch Mode6aa
aReproduced with permission from Elsevier (permission number: 4858900336289).
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2. RESULTS AND DISCUSSION
A three-step synthetic route has been used for the total
synthesis of goniothalamin in the batch mode in our laboratory
(Scheme 2).6a This procedure involves the addition of an
ethereal solution of allylmagnesium bromide (11) to trans-
cinnamaldehyde (10), followed by esterification of the
secondary alcohol 12 with acryloyl chloride (13) in the
presence of triethylamine to prepare the corresponding
acrylate ester 14. This is followed by a ring-closing metathesis
reaction using the Grubbs first-generation catalyst.
To explore the in vivo activity of this family of
dihydropyranones, this route was scaled up to provide gram
quantities of goniothalamin. Although such methodology was
able to secure ca. 25 g of the requisite (racemic) compound,
several small-scale batch reactions were required for the ring-
closing metathesis step, which did not provide acceptable
yields when conducted at a large scale or at an increased
concentration.8 On the practical side, manual work including
several chromatographic separations and the use of large
quantities of solvents were required to accumulate the requisite
amount of goniothalamin for in vivo studies.8 Based on this,
such a three-step batch procedure could be potentially adapted
to flow conditions to afford a more easily scaled approach.
Note that the desired process could not only potentially allow
the preparation of goniothalamin on a multigram scale but also
permit rapid access to analogues by changing the aldehyde and
Grignard reagent input starting materials.
2.1. Racemic Allylation Followed by Acylation
Reaction. To initiate experiments under continuous flow
conditions, the addition of allylmagnesium chloride (11) to
trans-cinnamaldehyde (10) was investigated. This step was
optimized by careful adjustment of the residence time and
stoichiometry toward full conversion to alcohol 12 before the
in-line introduction of the acylating agent in the following step.
The optimized flow conditions to alcohol (±)-12 are
presented in Scheme 3.
A commercially available THF solution of 11 (1.97 M) and
a THF solution of 10 were pumped through the flow reactor
via two chemically resistant peristaltic pumps containing
fluoropolymer tubes compatible with THF solutions, according
to our previous work concerning the processing of organo-
metallic reagents in a continuous flow regime.13 The
organometallic reagent solution was pumped from the
commercial bottle by inserting argon line through the septum
seal, with no requirement for predilution or use of sample
loops. Thus, Grignard reagent addition to 10 proceeded
quickly at room temperature. In batch, these reactions are
typically performed at low temperatures, for example, at 0 °C
or below, by dropwise addition, before warming up to room
temperature allowing the reaction to go to completion.6a In the
continuous flow regime, cryogenic conditions were not
Scheme 3. Continuous Flow Addition of Allylmagnesium Chloride (11, Pump B) to trans-Cinnamaldehyde (10, Pump A)
Scheme 4. Attempt toward Continuous Flow Addition of Allylmagnesium Chloride/Bromide (11, Pump B) to 10 (Pump A)
Followed by Acylation of the Alkoxide Intermediate with Acryloyl Chloride (13, Pump C)
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necessary and no uncontrollable exothermic reaction was
noticed, leading the reaction to achieve completion at reduced
residence times and increased material productivity. Notably,
while an uncontrollable exothermic process was not observed,
a modest temperature increase of 3−4 °C in the reactor was
noted when the cooling device of the flow system was not
operating, but neither yield nor selectivity were affected when
the results from processing in this way were compared with
those obtained from the active temperature control (through
cooling). Under the conditions shown in Scheme 3, full
conversion could be obtained using only 1.1 equiv of the
Grignard reagent 11. After reaching steady-state operation,
during a period of ca. 11.5 min, a sample was collected and,
after aqueous workup and chromatography purification,
alcohol 12 was obtained in 91% yield (1.83 g) and 9.5 g h−1
productivity, with a residence time of 6.67 min at the indicated
flow rates.
After optimizing the racemic allylation, the acylation
reaction was adapted from batch to the continuous flow
mode. The reaction of the secondary allylic alcohol 12 with
acryloyl chloride (13) is usually conducted in the batch mode
with triethylamine as base. However, the alkoxide product of
the Grignard addition eliminates the need for an additional
base in the acylation reaction. The output stream of the first
reactor coil was combined with a THF solution of 13, and the
combined stream was directed to an additional 10 mL reactor
coil kept at room temperature (Scheme 4).
Unfortunately, running the reaction under the conditions
depicted in Scheme 4 led to blockage of the system at the T-
piece where the alkoxide output and acylating reagent mix; we
hypothesized that this would be related to the precipitation of
magnesium(II) chloride in the reactor coil. The same behavior
was observed when allylmagnesium bromide was used instead
of the corresponding chloride. Reducing the reaction
concentration was explored but still led to the formation of
solids at the T-piece on mixing, resulting in blockage and
shutdown of the flow system.
Based on our previous work on the use of organometallic
reagents in the flow regime,13 13 was replaced by commercially
available crotonic anhydride (15) as the acylating agent,
leading instead to a more soluble mixed magnesium(II)
chloride acetate salt. Indeed, a THF solution of 15 was
pumped at 1.2 mL min−1 by the third peristaltic pump and
combined with the output stream from the first reactor coil,
which contained the alkoxide intermediate. The combined
stream was then directed to a second 10 mL reactor coil
stabilized at 50 °C and pressurized with an appropriate back-
pressure regulator. Ester 16 was obtained in full conversion
under these conditions.
Although the reaction conditions were optimized for the
telescoped preparation of ester 16, compatibility issues with
processing this Grignard reagent solution using peristaltic
pumps and supplied tubing led to irreproducible results (see
Figure S1 for more details), likely due to the presence of
remaining allyl chloride in the allylmagnesium chloride
solution.
To overcome this issue, an external piston pump (K-120
Knauer pump) was used to deliver the allylmagnesium chloride
solution, as shown in Figure S2. In this experiment, the back of
the HPLC-type piston pump was purged and connected to an
argon line. This measure avoids the exposure of the Grignard
solution to the atmosphere and formation of solids that would
result in blocking of the pumping system (see the Experimental
Section for more details).
Once the flow equipment and reaction parameters, such as
stoichiometry of reagents, residence time, and temperature,
were optimized, the multistep process for the preparation of
ester 16 was uninterruptedly run for 3 h to yield 20.9 g of the
product, which was obtained in full conversion and 96%
isolated yield, for 2 steps (Scheme 5).
With the racemic synthesis of the goniothalamin inter-
mediate (±)-16 in hand, we investigated the asymmetric
allylation to produce the (R)-goniothalamin precursor.
2.2. Asymmetric Allylation Reaction. Several batch
strategies have been proposed for the asymmetric synthesis of
goniothalamin (1).6a,14 For example, Singh and co-workers
employed an auxiliary-controlled asymmetric aldol reaction for
the construction of an enantiopure homoallylic alcohol
intermediate.14a Asymmetric allylboration was described by
Brown and co-workers, achieving homoallylic alcohol inter-
mediate (12) in 92−97% enantiomeric excess (ee).14b Our
group has previously employed Ti(Oi-Pr)4/(R)-BINOL-
mediated asymmetric allylation, leading to alcohol 12 in 78%
yield and 94% ee.6a,14c Enzymatic kinetic resolution of alcohol
12 has also been demonstrated.14d
Scheme 5. Continuous Flow Addition of Allylmagnesium Chloride (11, Pump B) to 10 (Pump A) Followed by Acylation of the
Alkoxide Intermediate with Crotonic Anhydride (15, Pump C)
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c02390
ACS Omega 2020, 5, 18472−18483
18475
Allylboranes and boronates derived from α-pinene or
diisopropyl tartrates as chiral auxiliaries have been utilized
for the enantio- and diastereoselective formation of homo-
allylic alcohols.15 Amongst the many reported methods for
asymmetric allylation, we chose to investigate these organo-
borane compounds in this context, in view of their
straightforward preparation employing readily available starting
materials and because of our continuing interest in exploring
the utility of flow chemistry for organometallic synthesis.
Moreover, high enantiomeric excess is usually obtained when
performing asymmetric allylation using this approach.15 Based
on this, both Brown (allylborane)15c and Roush (allylbor-
onates)15e reagents were prepared and initially evaluated in
batch for the asymmetric allylation of trans-cinnamaldehyde
(10) (Tables S1 and S2 in the SI). The Roush allylation
procedure with (+)- and (−)-diisopropyl-tartrate allyl
boronate (((+)- and (−)-DIPT)B(Allyl)) afforded homoallylic
alcohols (S)-12 and (R)-12 in 69−98% yield and 70.8−72.4%
ee (Table S1). On the other hand, the Brown procedure with
(−)-B-allyldiisopinocampheylborane ((−)-Ipc2B(Allyl)) af-
forded alcohol (S)-12 in 96% yield and 90.8% ee. In light of
these results, the Brown approach was taken forward for
optimization under continuous flow conditions (Table S3 in
the SI). The optimized result is presented in Scheme 6.
During optimization, an FTIR spectrometer was placed after
the coil reactor in the continuous flow system for the real-time
monitoring of the conversion of 10 into (S)-12. Such an
approach facilitates the reaction optimization, and (S)-12 was
obtained in 98% yield and 91.5 ee with a productivity of 1.57 g·
h−1. Gratifyingly, the chemical yield and the enantiomeric
excess obtained under continuous flow conditions at reduced
reaction times are slightly higher than those obtained in batch.
Probably, more efficient mixing of a 1:1 stoichiometric mixture
and improved temperature control in view of the high surface-
to-volume ratio of the flow reactor could account for this
superior outcome, as opposed to dropwise addition of one to
the other in batch. Note that compound (S)-12 could be
converted to the ester intermediate 14 or 16 and then to (S)-1
in batch using the conditions presented in Scheme 2. The need
for off-line work using hydrogen peroxide under basic
conditions would require an in-depth study to telescope into
the acylation under these conditions, probably making use of
the continuous membrane separation technology before
integration of the steps.
Finally, in the last step of the synthesis, the ring-closing
metathesis reaction to afford the α,β-unsaturated δ-lactone
present in the structure of goniothalamin (1) was evaluated.
2.3. Ring-Closing Metathesis Reaction. Numerous
immobilized Grubbs−Hoveyda catalysts for the ring-closing
metathesis reaction are reported in the literature,16 including
their investigation under continuous flow conditions.17 For
example, Zednić and co-workers demonstrated the metathesis
Scheme 6. Continuous Flow Asymmetric Allylation of trans-Cinnamaldehyde (10, Pump A) with (−)-Ipc2B(allyl) (Pump B),
Followed by In-Line Quenching with MeOH (Pump C)
Table 1. Evaluation of the Ring-Closing Metathesis in the Batch Mode
entry R catalyst loading (mol %) t (h) conversion (%)a 1/17/19 or 1/18/20a yield (1 + 19 or 1 + 20) (%)b yield 17 or 18 (%)
1 H Grubbs I 10 7.0 100 100:0:0 87 <5
2 H Grubbs II 5 1.5 100 97:0:3 90 <5
3 H Hoveyda II 5 1.5 100 94:0:6 95 <5
4 Me Grubbs I 10 14.0 96 20:80:0 19 75
5 Me Grubbs II 5 1.5 100 90:0:10 96 <5
6 Me Hoveyda II 5 3.0 100 92:8:0 92 8a
aCalculated from 1H NMR of the crude. bIsolated yield for the inseparable mixture.
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of cardanol using Hoveyda−Grubbs type catalysts supported
on mesoporous silica in the continuous flow regime.17a In this
study, the cumulative TON in flow was significantly improved
relative to the maximum TONs in a batch reactor (2500 versus
1600). The product contamination by metal leaching was also
verified, and only 1.0−1.5% of ruthenium was detected in the
final product. However, cardanol conversion fell over time due
to catalyst deactivation. Chmielewski and co-workers showed
the immobilization of ruthenium alkylidene complexes by
noncovalent interactions within metal−organic frameworks
(MOFs).17b Ruthenium leaching was not observed, but much
lower TONs were obtained in flow compared to batch
procedures (4700 versus 8900). A monolithic metathesis
catalyst was prepared by Kirschning and co-workers for further
use in a flow microreactor; however, it was affected by partial
leaching under continuous flow conditions.17c Other examples
include immobilization of Grubbs/Hoveyda catalysts on
commercial silica,17d microcapillaries coated with a film of
dimethylpolysiloxane soaked with the Grubbs second-gener-
ation catalyst,17e and the polystyrene-supported Grubbs
second-generation catalyst.17f
Even though the use of columns with packed immobilized
catalysts could be a convenient approach to minimize
postreaction manipulations, concerns such as leaching,
recycling, and anchoring of immobilized ruthenium catalysts
led us to focus our study on homogeneous conditions using
Grubbs first- and second-generation as well as Hoveyda−
Grubbs second-generation catalysts. Initially, we performed the
reactions in batch to evaluate the concentration and catalyst
selectivity (Table 1).
The ring-closing metathesis reaction for acrylate ester 14 is
typically performed using the Grubbs first-generation catalyst,
in refluxing dichloromethane and at low concentrations to
circumvent the formation of dimer 17 in view of the
intermolecular metathesis reaction.6a Indeed, under these
conditions (Table 1, entry 1), goniothalamin (1) was obtained
in good yield and selectivity from ester 14. On the other hand,
the use of either Grubbs or Hoveyda−Grubbs second-
generation catalysts led to the formation of goniothalamin
(1) along with the vinyl lactone 19 (Table 1, entries 2 and 3),
resulting from a cross-metathesis between the styryl unit of
goniothalamin (1) and ethylene gas, which is generated during
the ring-closing metathesis reaction (Scheme 7).
Reactions using crotonate ester 16, with the methyl group at
the acrylic unit, proved to be more complex. First, as one could
expect, the use of the Grubbs first-generation catalyst gave
dimer 18 as the major product with goniothalamin (1) being
isolated in only 19% yield (Table 1, entry 4). Note that both
goniothalamin (1) and 18 were also formed using the
Hoveyda−Grubbs second-generation catalyst; nevertheless,
the selectivity was reversed toward the formation of the
desired product goniothalamin (1) (entry 6). Finally, the ring-
closing metathesis of ester 16 carried out in the presence of the
Grubbs second-generation catalyst led to the formation of
goniothalamin (1) and lactone 20 in excellent combined yield
(96%), obtained as a 90:10 inseparable mixture (entry 5). All
additional experiments such as sparging with nitrogen gas to
force the removal of ethylene from the reaction mixture, slow
addition of the substrate and catalyst solutions (“infinite
dilution approach”) to reduce the amount of dimer 17 or 18
formation, reflux in toluene as solvent, higher reaction
concentration (up to 0.1 M), and using 1-heptene as a
sacrifice olefin (to avoid lactone 19/20 formation by reaction
with ethylene/propylene) proved to be unsuccessful (for more
details, see Table S4).
The very low concentrations usually employed for the ring-
closing metathesis reaction present an acute limitation of
material productivity when operating at large/pilot scales.18 In
batch, when the reaction with ester 16 was evaluated at higher
reaction concentrations (0.05 and 0.1 M), a more complex
mixture of dimers was observed.19 Bearing in mind the
aforementioned advantages of flow chemistry over batch
procedures, we sought to investigate the ring-closing meta-
thesis reaction in a continuous flow regime. Considering that
the monomeric α,β-unsaturated δ-lactone should be more
thermodynamically favorable than the dimer, pushing the
reaction in flow conditions to its limits could potentially
convert the observed dimer into goniothalamin (1), which
could enable the use of a higher concentration for this
transformation. The use of a back-pressure regulator to
pressurize the system allows the heating of a solvent above
its boiling point, and this fact was advantageously employed in
this synthesis.9
The flow setup used for the preliminary optimization
experiments is shown in Figure S3. Initially, the Grubbs first-
generation catalyst was evaluated in the reaction with esters 14
Scheme 7. Possible Reaction Pathways and Products for the Olefin Metathesis Reactiona
aCompounds enclosed in the blue dotted box were isolated and characterized; see the SI.
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and 16 at 100 °C (Table 2, entries 1 and 9). Low conversion
was obtained for ester 14 in 16 min of residence time. When
the more active and thermally stable Grubbs second-
generation catalyst was employed, full conversion was obtained
even at 50 °C, but a mixture of goniothalamin (1), dimer 17,
and lactone 19 was formed (entry 3). As we anticipated,
increasing the temperature led to the consumption of the
dimer and a mixture of 1 and lactone 19 was obtained in
almost 1:1 ratio (entry 4), being isolated in 78% combined
yield. The use of toluene as solvent at 150 °C (results not
shown) gave essentially the same results.
The formation of lactone by-product 19 in a greater extent
in the flow regime is not surprising, considering that the
reaction under flow conditions is performed in a closed system,
thus keeping the ethylene gas in solution, which favors the
olefin cross-metathesis reaction with the desired goniothalamin
(1) product (entries 2−5). Hypothesizing that such reaction
occurs after the ring-closing reaction, the residence time was
halved (entry 6). In this instance, for shorter residence time,
we observed a slightly lower conversion and the selectivity
remained poor (1:1 ratio of 1 and 19). The selectivity was
essentially the same when the Hoveyda−Grubbs second-
generation catalyst was investigated in the RCM reaction
(entries 7 and 8). Compound 19 could be converted back to
goniothalamin (1) using an olefin cross-metathesis reaction
with styrene. However, considering that both olefins should
present the same reactivity,20 a large excess of 19 or styrene
would be required in view of this nonselective cross-metathesis
reaction. Indeed, Das et al. performed the synthesis of
goniothalamin (1) using this strategy; however, a large excess
of 19 (20 equiv) was employed.20
The reaction with ester 16 in the presence of Grubbs and
Hoveyda−Grubbs second-generation catalysts yielded better
selectivities (entries 10 and 13), which could be explained by
the lower reactivity of the propylene by-product in the cross-
metathesis reaction. Surprisingly, the reaction carried out
under identical conditions, but at a lower molar concentration
(entry 10, 0.01 M), afforded goniothalamin (1) as a single
product, although in a lower conversion (80%). Such similar
results were not observed using ester 14 (entries 2 and 4). The
higher dilution combined with the lower reactivity of
propylene completely suppressed the intermolecular cross-
metathesis reaction. However, this reaction performed under
essentially identical conditions but with a longer residence time
gave comparable results, indicating that the reaction reached
equilibrium.21 Finally, the selectivity was found to decrease at a
higher reaction concentration of ester 16 in both Grubbs and
Hoveyda−Grubbs second-generation catalysts (entries 12 and
14).
Additional olefin metathesis experiments were performed
using a gas−liquid tube-in-tube flow reactor. The tube-in-tube
reactor relies on the use of a semipermeable membrane
(Teflon AF-2400), which allows the loading of the desired gas
into the liquid stream in view of its permeation through the
membrane. In the last decade, several reactions have been
explored using this membrane technology.22 For example,
Knapkiewicz and co-workers demonstrated homo- and
heterogeneous olefin metathesis using a tube-in-tube reactor
of this type.23 In this configuration, ethylene was continuously
removed by connecting the reactor to a vacuum pump, and
substantial improvement was perceived for macrocyclization
metathesis reactions. Based on this precedent, the same
strategy was evaluated for this study (Table S5). However, no
Table 2. Evaluation of the Ring-Closing Metathesis toward Goniothalamin (1) under Flow Conditions
entry R conc. (M) catalyst loading (mol %) T (°C) t (min) conv. (%)a 1/17/19 or 1/18/20a yield (1 + 19 or 1 + 20) (%)b
1 H 0.05 Grubbs I 10 100 16.0 23 100:0:0 NDc
2 H 0.01 Grubbs II 5 100 16.0 90 79:0:21 90
3 H 0.05 Grubbs II 5 50 16.0 100 38:44:18 55
4 H 0.05 Grubbs II 5 100 16.0 100 57:0:43 78
5 H 0.05 Grubbs II 1 100 16.0 55 83:0:17 NDc
6 H 0.05 Grubbs II 5 100 8.0 97 54:0:46 79
7 H 0.01 Hoveyda II 5 100 16.0 100 44:0:56 97
8 H 0.05 Hoveyda II 5 100 16.0 100 41:0:59 58
9 Me 0.05 Grubbs I 10 100 16.0 0
10 Me 0.01 Grubbs II 5 100 16.0 80 100:0:0 75 (1 only)
11 Me 0.01 Grubbs II 5 100 32.0 75 100:0:0 65 (1 only)
12 Me 0.05 Grubbs II 5 100 16.0 100 66:0:34 94
13 Me 0.01 Hoveyda II 5 100 16.0 100 83:0:17 91
14 Me 0.05 Hoveyda II 5 100 16.0 100 63:0:37 77
aCalculated from 1H NMR of the crude. bIsolated yield for the inseparable mixture. cND = not determined.
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improvement was observed using a tube-in-tube reactor (90
cm; 1.25 mL·min−1 flow rate) for ester 14, i.e., the same
selectivity and yield compared to entry 4 in Table 2 was found
using this reactor. In our case, the cyclization step is likely to
be fast, meaning that the catalyst turnover is quick enough to
compete with ethylene removal. Conversely, in the macro-
cyclization reaction, the resting state would likely be substrate
bound to catalyst before cyclization, meaning ethylene has
more time to be purged.
The use of sacrifice olefin (1-heptene) in the flow regime
was also explored but led to no improvements (Table S5).
Although all attempts to improve the selectivity of this RCM
reaction at higher concentrations failed, it is worth mentioning
that continuous flow processing could at least deliver
significant conversions in tighter residence times than batch
protocols using the same concentration.
In view of the limitation imposed by the formation of the
lactone by-products 19 and 20 and the high dilution issues
under different flow strategies, which in turn presents a
constraint for throughput and productivity, we decided to
perform the final step in the synthesis of goniothalamin (1) on
a preparative scale in the batch mode (Scheme 8). For this
reaction, a 12 g sample of ester 16 was employed in the ring-
closing metathesis reaction using the Grubbs second-
generation catalyst. The reaction was performed with sparging
of nitrogen gas and heated to reflux in dichloromethane. Full
conversion of the substrate was observed after 1.5 h of
reaction, and the target product was isolated in 78% yield
(7.75 g). However, lactone 20 was also isolated in 19% yield.24
In comparison to the same reaction performed at 1 mmol scale
(Table 1, entry 5), the overall chemical yield was similar;
however, the selectivity was affected by the less efficient
elimination of the propylene gas from the reaction mixture, in
view of the poorer surface area-to-volume ratio that occurs in a
larger batch vessel (10 L) under conventional magnetic
stirring. Although good quantities of the desired compound
could be obtained, this result highlights the current limitations
of our synthetic approach and equipment capabilities as far as
scale-up is concerned.
As new reactor technologies emerge, the synthesis and
preparation of chemicals of interest should be re-evaluated to
look for more streamlined approaches;25 herein, our current
best route to goniothalamin (1) consists of two flow steps
followed by a batch process.
3. CONCLUSIONS
In summary, the synthesis of the styryl lactone goniothalamin
(1) was investigated in a continuous flow regime. The 1,2-
addition of the Grignard reagent to trans-cinnamaldehyde (10)
and the acylation reaction of the resulting allylic alcohol 12
could be combined in a telescoped process leading to the
formation of ester 16 in 96% yield, for two steps. Running this
sequence by continuously pumping the starting materials over
a period of 3 h led to the preparation of 20.9 g of material,
giving a productivity of 7 g·h−1. An asymmetric Brown
allylation reaction was also demonstrated in a continuous flow,
leading to excellent yield (98%) and ee (91.5%) for (S)-12.
The ring-closing metathesis reaction was evaluated in batch
and flow conditions using three different ruthenium catalysts.
In the batch mode, the reaction could be performed with good
to excellent selectivities to give goniothalamin (1) in excellent
yield (up to 96%). The use of the Grubbs second-generation
catalyst proved to be very efficient, and the reaction time
decreased from 7 to 1.5 h in comparison to the use of the
Grubbs first-generation catalyst, even at lower catalyst loadings.
Even though full conversion could be obtained in a short
residence time under continuous flow conditions, selectivity
and yield were negatively affected due to the entrapment of
ethylene or propylene. In the closed flow system, the evolving
gases underwent an olefin cross-metathesis reaction with the
styryl moiety of goniothalamin (1) affording lactones 19 or 20,
in up to a 1:1 molar ratio. Different flow strategies, including a
tube-in-tube reactor for ethylene/propylene removal and
sacrifice of olefin, were unsuccessfully employed. On the
other hand, good yield and selectivity could be achieved in
flow at reduced residence times at the cost of incomplete
conversion (16 min, 80% conversion, and 75% yield) using a
more dilute solution. In view of the formation of by-products
and high dilution issues, which in turn presents a limitation for
throughput and productivity, a preparative-scale synthesis of
goniothalamin (1) was performed under the optimized batch
conditions. In this way, 7.75 g of goniothalamin (1) was
obtained in 78% yield. Our work demonstrates that the
combination of batch and continuous flow processes is a useful
strategy when one or more steps of a target molecule can be
maximized in terms of selectivity and yield.
4. EXPERIMENTAL SECTION
4.1. Materials and Methods. Reagents were obtained
from commercial sources and used as received unless otherwise
stated. All reactions were carried out with anhydrous solvents,
oven-dried glassware (200 °C), and manipulated under an
argon atmosphere unless otherwise stated. Tetrahydrofuran
(THF) was freshly distilled under argon from sodium/
benzophenone ketyl prior to use. Allylmagnesium chloride, at
a concentration of 2.0 M in THF, was obtained from Sigma-
Aldrich and titrated before its use. When necessary, dilution
was performed by the addition of anhydrous THF.
Compounds 1, 12, and 16 were purified by flash column
chromatography using a Biotage Isolera system using
prepacked silica gel 60 Å cartridges. TLC analysis was
performed utilizing 0.25 mm plates precoated with silica gel
60 UV254, with the compounds being visualized by the use of
UV light and/or aqueous potassium permanganate dip when
appropriate. 1H NMR and 13C NMR data were recorded on a
Bruker Avance (400 MHz for 1H and 100 MHz for 13C NMR)
spectrometer using the residual solvent peak as the internal
reference (CDCl3 = 7.26 ppm for
1H and 77.0 ppm for 13C).
Scheme 8. Preparative-Scale Synthesis of Goniothalamin (1) in the Batch Mode
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The data are reported as follows: chemical shift in ppm (δ),
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet,
quint = quintet, m = multiplet, br = broad signal, or
combinations of thereof), coupling constant (Hz), integration.
Enantiomeric excess (% ee) for Roush and Brown allylation
reactions was determined by chiral HPLC: 99:01 n-hexanes/i-
PrOH, CHIRALPAK AD-H, 0.9 mL·min−1, 46 and 49 min.
Reactors and interconnecting lines were constructed using a
PFA polymer tubing of 1.0 mm i.d., the exception being the
fluoropolymer peristaltic tubes, which were supplied by
Vapourtec. Most of the experiments were carried out using a
Vapourtec E-series flow system and the cooled reactor
assembly, except for the preparation of compound 16, where
an external pump (K-120 Knauer pump) was used to deliver
the Grignard Reagent. A Uniqsis FlowSyn System was used in
the study of the RCM reaction. Please see the SI for pictures of
the flow equipment and setups discussed and used.
For setting up the peristaltic flow system for each
experiment and cleaning down afterward, we followed the
general protocol reported in our previous study on the
pumping of organometallic reagents.13a
4.2. Continuous Flow Synthesis of (E)-1-Phenylhexa-
1,5-dien-3-ol (12). The flow system was set up according to
Scheme 3. A 1.0 M solution of trans-cinnamaldehyde (10) in
anhydrous THF (100 mL), under argon, was combined at a T-
piece with a 1.97 M solution of allylmagnesium chloride (11)
in anhydrous THF (100 mL), under the flow rates indicated in
Scheme 3. The combined stream was passed through a coil
reactor (10 mL) kept at 25 °C with continuous cooling and
pressurized by a 75 psi back-pressure regulator. After the
steady-state operation, the output stream was collected over
11.5 min into a conical flask containing a saturated aqueous
ammonium chloride solution (50 mL) at room temperature
under stirring. The collected material was transferred to a
separatory funnel, and the aqueous phase was extracted with
diethyl ether (3 × 50 mL). The combined organic phase was
dried over anhydrous magnesium sulfate, filtered, and
concentrated to dryness. The crude product was subjected to
flash column chromatography on silica using the Biotage
autocolumn system, eluting in 5−10% ethyl acetate/petroleum
ether 40−60 to give alcohol 12 in 91% yield (1.83 g), obtained
as a colorless viscous oil.
4.3. Telescoped Synthesis of (E)-((E)-1-Phenylhexa-
1,5-dien-3-yl) but-2-enoate (16). 4.3.1. Procedure A:
Using the Vapourtec E-Series (Pumps A−C). The flow system
was set up according to Scheme 5. A 0.5 M solution of trans-
cinnamaldehyde (10) in anhydrous THF (250 mL), under
argon, was combined at a T-piece with a 0.89 M solution of
allylmagnesium chloride (11) in anhydrous THF (250 mL).
The combined stream was passed through a PFA reactor coil
(10 mL) kept at 25 °C with continuous cooling. The output
stream was combined in-line at a T-piece with a 0.5 M solution
of crotonic anhydride in anhydrous THF (250 mL). The new
combined stream was passed through a second PAF reactor
coil (10 mL) held at 50 °C, and the whole system was
pressurized by a 75 psi back-pressure regulator. The three
solutions were pumped at the flow rates indicated in Scheme 5.
After the steady-state operation, the output stream was
collected over 10 min into a conical flask containing a
saturated aqueous ammonium chloride solution (100 mL) at
room temperature under stirring. The collected material was
transferred to a separatory funnel, and the aqueous phase was
extracted with diethyl ether (3 × 30 mL). The combined
organic phase was dried over anhydrous magnesium sulfate,
filtered, and concentrated to dryness. The crude product was
subjected to flash column chromatography on silica using the
Biotage autocolumn system, eluting in 4−30% ethyl acetate/
petroleum ether 40−60, to afford ester 16 in 73% yield (0.89
g), obtained as a light-yellow oil.
4.3.2. Procedure B: Using the Vapourtec E-Series (Pumps
A and C) and the K-120 Knauer Pump. The flow system was
set up according to Scheme 5. A 0.5 M solution of trans-
cinnamaldehyde (10) in anhydrous THF (250 mL), under
argon, was combined at a T-piece with a 0.88 M solution of
allylmagnesium chloride (11) in anhydrous THF (100 mL).
The combined stream was passed through a PFA reactor coil
(10 mL) kept at 25 °C with continuous cooling. The output
stream was combined in-line at a T-piece with a 0.5 M solution
of crotonic anhydride in anhydrous THF (250 mL). The new
combined stream was passed through a second PAF reactor
coil (10 mL) held at 50 °C, and the whole system was
pressurized by a 75 psi back-pressure regulator. The three
solutions were pumped at the flow rates indicated in Scheme 5.
After the steady-state operation, the output stream was
collected over 3 h into a conical flask containing a saturated
aqueous ammonium chloride solution (400 mL) at room
temperature under stirring. The collected material was
transferred to a separatory funnel, and the aqueous phase
was extracted with diethyl ether (2 × 200 mL). The combined
organic phase was dried over anhydrous magnesium sulfate,
filtered, and concentrated to dryness. The crude product was
subjected to flash column chromatography on silica using the
Biotage autocolumn system, eluting in 1−30% ethyl acetate/
petroleum ether 40−60, to afford ester 16 in 96% yield (20.9
g), obtained as a light-yellow oil.
4.4. Procedure for the Continuous Flow Asymmetric
Allylborane Addition to trans-Cinnamaldehyde (10).
The flow system was set up according to Scheme 6, and the
reactor assembly was kept at −78 °C, due to the exothermic
reaction. A 0.5 M solution of trans-cinnamaldehyde (10) in
anhydrous Et2O (100 mL), under argon, was combined at a T-
piece with a 0.6 M solution of (−)-B-allyldiisopinocamphe-
nylborane in anhydrous Et2O (100 mL). The combined stream
was passed through a PFA reactor coil (10 mL) kept at −78 °C
with continuous cooling. The output stream of the reactor was
combined in-line with neat MeOH (250 mL), and the whole
system was pressurized by a 100 psi back-pressure regulator.
The three solutions were pumped at the flow rates indicated in
Scheme 6. After the steady-state operation, the output stream
was collected over 15 min into a round-bottomed flask (50
mL) containing 10 mL of 30% aq H2O2/3 M NaOH aq at 0
°C under stirring. Next, the resulting solution was warmed up
to rt over 1 h. The collected material was transferred to a
separatory funnel, and the aqueous phase was extracted with
diethyl ether (3 × 50 mL). The combined organic phase was
dried over anhydrous magnesium sulfate, filtered, and
concentrated to dryness. The crude product was subjected to
flash column chromatography on silica using the Biotage
autocolumn system, eluting in 5−10% ethyl acetate/petroleum
ether 40−60, to afford the alcohol (S)-12 in 98% yield (391.5
mg), obtained as a colorless viscous oil.
4.5. Segmented Continuous Flow Ring-Closing Meta-
thesis Reaction. Procedure for the flow preparation of
goniothalamin (1) (exemplified for entry 12, Table 2).
The Uniqsis FlowSyn reactor was fitted with two 5 mL
injection loopings and attached to a PFA reactor coil (16 mL,
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c02390
ACS Omega 2020, 5, 18472−18483
18480
1.0 mm i.d.), which was placed on a heating block. The system
was primed with CH2Cl2 at a flow rate of 0.5 mL/min per
channel and the temperature was set to 100 °C. A solution of
ester 16 in dry CH2Cl2 (0.1 M, 0.5 mmol, 5.0 mL) and a
solution of Grubbs second-generation catalyst in dry CH2Cl2
(5 mol %, 0.025 mmol, 5 mL) were loaded into two 5 mL
injection loopings (injection loopings A and B, Figure S3). To
initiate, injection loopings A and B were simultaneously
inserted into the main flow stream via a T-piece connector at a
flow rate of 0.5 mL/min per channel. The combined stream
was then directed through a PFA reactor coil (16 mL, 1.0 mm
i.d.), which was maintained at 100 °C, giving a residence time
of 16 min. After exiting the system via a BPR (6.0 bar), the
output stream was collected during 30 min in a conical flask.
The solution was passed through a plug of silica flash, and the
volatiles were removed under vacuum. The crude product was
subjected to flash column chromatography on silica using the
Biotage autocolumn system, eluting in 20−60% ethyl acetate/
petroleum ether 40−60, to afford an inseparable mixture of
goniothalamin (1) and lactone 20 in 94% combined yield.
4.6. Procedure for the Batch Preparation of
Goniothalamin (1). To a solution of ester 16 (50 mmol)
in anhydrous CH2Cl2 (5.0 L, 0.01 M) was added the Grubbs
second-generation catalyst (5 mol %, 2.5 mmol, 2.1 g). After
1.5 h under reflux, the reaction was allowed to cool down to
room temperature, DMSO (50 equiv relative to the catalyst)
was added, and the mixture was kept under these conditions
overnight. After that, the volatiles were removed under vacuum
and the crude product was subjected to flash column
chromatography (petroleum ether 40−60/ethyl acetate 3:1,
2:1, and 1:1 v/v) to afford goniothalamin (1) in 78% yield
(7.75 g) and lactone 20 in 19% yield (0.81 g).
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